Combined approach for predicting the efficacy of nivolumab in head and neck carcinoma by tissue and soluble expressions of PD-L1 and PD-L2.
Ryosuke SatoHiroki KomatsudaTakahiro InoueRisa WakisakaMichihisa KonoHidekiyo YamakiKenzo OharaTakumi KumaiKan KishibeTatsuya HayashiMiki TakaharaPublished in: Head & neck (2024)
Our study revealed that compared to PD-L1 expression alone, dual expression of PD-L1 and PD-L2 in tissue or soluble form could be feasible biomarkers in patients with RMHNSCC who received nivolumab.
Keyphrases